Nuria Salazar1, Evelyne M Dewulf1, Audrey M Neyrinck1, Laure B Bindels1, Patrice D Cani1, Jacques Mahillon2, Willem M de Vos3, Jean-Paul Thissen4, Miguel Gueimonde5, Clara G de Los Reyes-Gavilán5, Nathalie M Delzenne6. 1. Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium. 2. Laboratory of Food and Environmental Microbiology, Earth and Life Institute, Université Catholique de Louvain, Louvain-la-Neuve, Belgium. 3. Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands; Department of Bacteriology & Immunology, University of Helsinki, Helsinki, Finland. 4. Pole of Endocrinology, Diabetology and Nutrition, Université Catholique de Louvain, Brussels, Belgium. 5. Department of Microbiology and Biochemistry of Dairy Products, Instituto de Productos Lácteos de Asturias, Consejo Superior de Investigaciones Científicas (IPLA-CSIC), Villaviciosa, Asturias, Spain. 6. Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium. Electronic address: nathalie.delzenne@uclouvain.be.
Abstract
BACKGROUND & AIMS:Inulin-type fructans (ITF) prebiotics promote changes in the composition and activity of the gut microbiota. The aim of this study was to determine variations on fecal short chain fatty acids (SCFA) concentration in obese women treated withITF and to explore associations between Bifidobacterium species, SCFA and host biological markers of metabolism. METHODS: Samples were obtained in a randomized, double blind, parallel, placebo-controlled trial, with 30 obese women randomly assigned to groups that received either 16 g/day ITF (n = 15) or maltodextrin (n = 15) for 3 months. The qualitative and quantitative analysis of Bifidobacterium spp. was performed in feces by PCR-DGGE and q-PCR, and SCFA profile was analyzed by gas chromatography. Spearman correlation analysis was performed between the different variables analyzed. RESULTS: The species Bifidobacterium longum, Bifidobacterium pseudocatenulatum and Bifidobacterium adolescentis were significantly increased at the end of the treatment in the prebiotic group (p < 0.01) with being B. longum negatively correlated with serum lipopolysaccharide (LPS) endotoxin (p < 0.01). Total SCFA, acetate and propionate, that positively correlated with BMI, fasting insulinemia and homeostasis model assessment (HOMA) (p < 0.05), were significantly lower in prebiotic than in placebo group after the treatment period. CONCLUSIONS:ITF consumption selectively modulates Bifidobacterium spp. and decreases fecal SCFA concentration in obese women. ITF could lessen metabolic risk factors associated with higher fecal SCFA concentration in obese individuals.
RCT Entities:
BACKGROUND & AIMS: Inulin-type fructans (ITF) prebiotics promote changes in the composition and activity of the gut microbiota. The aim of this study was to determine variations on fecal short chain fatty acids (SCFA) concentration in obesewomen treated with ITF and to explore associations between Bifidobacterium species, SCFA and host biological markers of metabolism. METHODS: Samples were obtained in a randomized, double blind, parallel, placebo-controlled trial, with 30 obesewomen randomly assigned to groups that received either 16 g/day ITF (n = 15) or maltodextrin (n = 15) for 3 months. The qualitative and quantitative analysis of Bifidobacterium spp. was performed in feces by PCR-DGGE and q-PCR, and SCFA profile was analyzed by gas chromatography. Spearman correlation analysis was performed between the different variables analyzed. RESULTS: The species Bifidobacterium longum, Bifidobacterium pseudocatenulatum and Bifidobacterium adolescentis were significantly increased at the end of the treatment in the prebiotic group (p < 0.01) with being B. longum negatively correlated with serum lipopolysaccharide (LPS) endotoxin (p < 0.01). Total SCFA, acetate and propionate, that positively correlated with BMI, fasting insulinemia and homeostasis model assessment (HOMA) (p < 0.05), were significantly lower in prebiotic than in placebo group after the treatment period. CONCLUSIONS: ITF consumption selectively modulates Bifidobacterium spp. and decreases fecal SCFA concentration in obesewomen. ITF could lessen metabolic risk factors associated with higher fecal SCFA concentration in obese individuals.
Authors: Jun Zou; Benoit Chassaing; Vishal Singh; Michael Pellizzon; Matthew Ricci; Michael D Fythe; Matam Vijay Kumar; Andrew T Gewirtz Journal: Cell Host Microbe Date: 2017-12-21 Impact factor: 21.023
Authors: Jessie B Hoffman; Michael C Petriello; Andrew J Morris; M Abdul Mottaleb; Yipeng Sui; Changcheng Zhou; Pan Deng; Chunyan Wang; Bernhard Hennig Journal: Environ Pollut Date: 2020-02-20 Impact factor: 8.071
Authors: Ethan A Mezoff; Jennifer A Hawkins; Nicholas J Ollberding; Rebekah Karns; Ardythe L Morrow; Michael A Helmrath Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-12-23 Impact factor: 4.052